Surgical aortic valve replacement is the sole validated treatment of aortic stenosis. The indications for surgery rely on risk/benefit ratio and on the official recommendations. A symptomatic patient with severe aortic stenosis should be submitted to surgery. The indication of valve replacement is more difficult in asymptomatic patients. The decision should integrate a combination of an exercise test and prognostic parameters associated with poor outcome. Most of them are obtained by Doppler echocardiography. Patients presenting with severe aortic stenosis and low transvalvular gradient constitute a subgroup of patients who require appropriate echocardiographic assessment to determine the potential benefit and risk of surgery. Transluminal aortic valve implantation is a new modality for patients at high surgical risk.
Download full-text PDF |
Source |
---|
Cardiovasc Diabetol
January 2025
Department of Cardiology, the First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, China.
Background: Triglyceride-glucose-BMI (TyG-BMI) index is a surrogate marker of insulin resistance and an important predictor of cardiovascular disease. However, the predictive value of TyG-BMI index in the progression of non-severe aortic stenosis (AS) is still unclear.
Methods: The present retrospective observational study was conducted using patient data from Aortic valve diseases RISk facTOr assessmenT andprognosis modeL construction (ARISTOTLE).
JACC Cardiovasc Interv
January 2025
Ascension St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.
Background: The optimal timing for percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) is debatable.
Objectives: The aim of this study was to compare outcomes based on the timing of PCI in stable coronary artery disease patients undergoing TAVR.
Methods: Leveraging the STS/ACC TVT Registry and Medicare Linkage, we analyzed patients with stable coronary artery disease undergoing PCI and TAVR between 2015 and 2023 using the SAPIEN 3 balloon-expandable valve platform.
JACC Cardiovasc Interv
January 2025
Institut Cardiovasculaire Paris-Sud, Hôpital Privé Jacques Cartier, Ramsay-Santé, Massy, France. Electronic address:
Background: The prevalence of coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is high. Treatment of a coronary events (CE) after TAVR can be technically challenging.
Objectives: The authors sought to assess the incidence and prognostic impact of CE after TAVR.
J Cardiothorac Vasc Anesth
January 2025
Division of Congenital Cardiac Anesthesiology, University of Alabama at Birmingham School of Medicine, Birmingham, AL; Bruno Pediatric Heart Center, Children's of Alabama, Birmingham, AL. Electronic address:
JACC Cardiovasc Interv
January 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Cardio Center, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!